Patient education would aid compliance

Article

To help improve compliance, patients should be made aware of what a normal intraocular pressure (IOP) is and be informed of their own at each visit to their ophthalmologist, according to Rohit Arora and colleagues from the North Middlesex Hospital, UK.

To help improve compliance, patients should be made aware of what a normal intraocular pressure (IOP) is and be informed of their own at each visit to their ophthalmologist, according to Rohit Arora and colleagues from the North Middlesex Hospital, UK.

In their study, a structured questionnaire was completed by 100 patients attending a glaucoma clinic with chronic open angle glaucoma and ocular hypertension. Questions related to field defects, IOP, treatment and compliance. Their aim was to test patients' knowledge of the condition and therapy and to relate this to treatment compliance.

The investigators found that 13% of patients were unaware that they had glaucoma, however, 87% were aware that the disease has a very serious effect on vision. Forty-seven percent were able to accurately remember the name of their drops, 30% had an appropriate idea but 23% had no idea.

In terms of compliance, 18% depended on family members for the drops, 53% claimed full compliance, 14% admitted to forgetting their drops once in every 15 days, 14% would forget once a month and 20% would forget once in every six months. The main causes of non-compliance were holidays and general forgetfulness.

A significant number, 87%, had no idea about their own IOP and about the pressure range of a normal eye, whilst 80% did not understand the technique or relevance of the field tests. Sixty-four percent were unaware of alternative treatment options and 73% did not know of the existence of helplines and societies.

The team concluded from the study that patients needed to be further educated about the nature of their disease as this would serve to enhance compliance.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.